Alcon

How to Choose the Best Lasik Vision Correction Procedure

The Health & Fitness Blog (Free subscription) | yesterday

By Zack Rafael Do you wish you didn't have to keep using glasses and contact lenses? If so, then Lasik surgery may be exactly what you are looking for. It is a kind of vision correction surgery for the eye involving laser technology. The word 'Lasik' is an abbreviation of the phrase 'laser in situ keratomileusis'. In this procedure, a laser is used under the flap of the cornea. The shape of the cornea...

Low Price Alcon ICaps Multivitamin Eye Vitamin & Mineral Support, Coated Tablets , 100 tablets

Health Care Products Reviews (Free subscription) | 03/11/2009

My ophthalmalogist prefers the I-Cap formulation to its competitor. The daily dosage is 4 pills, which is both plus and a minus.Get more detail about Alcon ICaps Multivitamin Eye Vitamin & Mineral Support, Coated Tablets , 100 tablets. [[ This is a content summary only. Visit my website for full links, other content, and more! ]]

Alcon (ACL) Down Slightly Over 1% Friday And Is Trading Just Shy Of Its 52 Week High With Bullish Technicals

MarketIntelligenceCenter.com (Free subscription) | 02/11/2009

Alcon (NYSE: ACL) ended the last trading session at $142.79. So far the stock has hit a 52-week low of $66.64 and 52-week high of $148.85. Alcon stock has been showing support around 140.22 and resistance in the 146.96 range. Technical indicators for the stock are Bullish and S&P gives ACL a positive 4 STAR (out of 5) buy rating. ACL appears on the Investors Observer Momentum Plays list. For a...

Earnings roundup: CommVault, Alcon

Rocky Mount Telegram - Business (Free subscription) | 29/10/2009

OCEANPORT, N.J. (AP) — CommVault Systems Inc. reported a flat fiscal second-quarter profit as ...

• Earnings roundup: CommVault, Alcon - Daily Advance - Business
• Earnings roundup: CommVault, Alcon - San Fransisco Chronicle
• See the 4 articles on the same subject

Earnings roundup: CommVault, Alcon

Seattle Times (Free subscription) | 28/10/2009

Among the earnings stories for Wednesday, Oct. 28, from AP Financial News:

Alcon profit falls from year-ago period helped by tax benefit, but still beats estimates

Star Tribune (Free subscription) | 28/10/2009

The Swiss company said surgical product revenue grew 7 percent to $739 million, and pharmaceutical revenue rose 8 percent to $659 million. Consumer eye care product revenue fell 3 percent to $216 million.

Alcon 3Q profit down 18 percent without tax gain

San Fransisco Chronicle (Free subscription) | 28/10/2009

Eye drug maker Alcon Inc. said Wednesday its profit fell 18 percent in the third quarter compared with a year ago, when it received a large tax benefit. Alcon's profit slipped to $515 million, or $1.71 per share, from $627 million, or $2.07 per share, in the... Sponsored Topics: Tax - Taxation - United States - Accounting - Society and Culture

• Alcon 3Q profit down 18 percent without tax gain - Seattle Times
• Alcon 3Q profit down 18 percent without tax gain - Seattle Post-Intelligencer

Alcon Posts 5.9 Percent Sales Growth for Third Quarter

Business Wire (Free subscription) | 27/10/2009

HUENENBERG, Switzerland--(BUSINESS WIRE)--Alcon, Inc. (NYSE:ACL) reported global sales rose 5.9 percent to $1,614 million for the third quarter of 2009, or a 9.0 percent increase excluding the impact of foreign exchange fluctuations. Net earnings for the third quarter of 2009 were $515 million, or $1.71 per diluted share. Excluding the impact of a $240 million tax benefit related to the refractive...

Potentia reaches deal to license drug to Alcon

The Business First of Louisville (Free subscription) | 23/10/2009

Potentia Pharmaceuticals, a Louisville-based startup biotechnology company, has reached an agreement to license an age-related macular degeneration drug it is working on to Alcon Research Ltd., a Swiss pharmaceutical company that focuses on eye-care products.

Potentia, Alcon ink AMD drug deal

Fiercebiotech (Free subscription) | 23/10/2009

Potentia Pharmaceuticals has signed a licensing and purchase agreement with eye drug company Alcon. Alcon gets a license to develop Potentia's leading drug candidate, POT-4, for the treatment of AMD. Potentia gains undisclosed upfront and milestone payments, which the Louisville Courier-Journal says could be worth hundreds of millions of dollars to the Kentucky-based Potentia. The agreements also...

Potentia Pharmaceuticals Enters into Licensing and Purchase Option Agreements with Alcon

PR News Wire (Free subscription) | 23/10/2009

LOUISVILLE, Ky., Oct. 23 /PRNewswire/ -- Potentia Pharmaceuticals, a privately-held biotechnology company developing medicines for the treatment of age-related macular degeneration (AMD), announced today that it has entered into licensing and purchase option agreements with Alcon Research, Ltd., a wholly-owned subsidiary of Alcon, Inc. (NYSE: ACL). The agreements provide Alcon with a license to develop...

Potentia Pharmaceuticals Enters into Licensing and Purchase Option Agreements with Alcon

Red Orbit (Free subscription) | 23/10/2009

LOUISVILLE, Ky., Oct.

Nestle speeds up share buyback, may sell Alcon stake

Indian Express (Free subscription) | 23/10/2009

Cash-rich Nestle SA, the world's biggest food group, said it was speeding up a program to buy back shares and was likely to raise fresh funds from the sale of its stake in eye care firm Alcon.

Nestle speeds ups buyback; sales growth in line

Daily News Analysis (Free subscription) | 22/10/2009

Nestle did not comment on whether it will exercise an option to sell its 52% stake in eye care subsidiary Alcon to Novartis.

Nestle Raises Share Buyback Target as Sales Decline 2.2%, Alcon Sale Looms

Bloomberg (Free subscription) | 22/10/2009

Oct. 22 (Bloomberg) -- Nestle SA, the world’s largest food company, raised this year’s buyback target and repeated its forecast that profitability will increase, mitigating a sales decline as consumers turned away from bottled water.